| Cat. No. |
Product Name |
Information |
| PC-61681 |
Oliceridine
MOR agonist
|
Oliceridine (Olinvo, TRV130) is a potent, selective, and G protein biased μ opioid receptor (MOR) agonist with pEC50 of 8.1. |
| PC-61596 |
SR-8993
NOP-R agonist
|
SR-8993 is a potent, highly selective, brain-penetrant NOP-R (Nociceptin/orphanin FQ receptor) agonist with EC50 of 8.8 nM. |
| PC-61588 |
MK-1925
ORL1 agonist
|
MK-1925 is a selective, orally active, brain-penetrant opioid receptor-like 1 (ORL1. |
| PC-61550 |
AT-127
NOP receptor agonist
|
AT-127 is a potent, selective nociceptin/orphanin FQ receptor (NOP receptor) agonist with Ki of 1.18 nM. |
| PC-61549 |
AT-090
NOP receptor agonist
|
AT-090 is a potent, selective nociceptin/orphanin FQ receptor (NOP receptor) agonist with Ki of 5.61 nM. |
| PC-61547 |
SB-612111
NOP receptor antagonist
|
SB-612111 is a potent, selective nociceptin/orphanin FQ receptor (NOP receptor) antagonist with Ki of 0.33 nM. |
| PC-61546 |
LY2940094
NOP receptor antagonist
|
LY2940094 (BTRX-246040) is a potent, selective, CNS-penetrant, orally available NOP (Nociceptin/OFQ) receptor antagonist with Kb of 0.17 nM. |
| PC-61545 |
J-113397
NOP antagonist
|
J-113397 is a potent, selective nociceptin/orphanin FQ receptor (NOP receptor/ORL1) antagonist with IC50 of 2.3 nM. |
| PC-61544 |
Ro 64-6198
NOP agonist
|
Ro 64-6198 is a nonpeptidic, selective, brain-penetrant agonist of nociceptin/orphanin FQ receptor (NOP receptor/ORL1) with pKi of 9.41. |
| PC-61543 |
Ro 64-6198 hydrochloride
ORL1 agonist
|
Ro 64-6198 hydrochloride is a nonpeptidic, selective, brain-penetrant agonist of nociceptin/orphanin FQ receptor (NOP receptor/ORL1) with pKi of 9.41. |
| PC-61542 |
MT-7716
ORL1 agonist
|
A highly potent, brain-penetrating ORL1 receptor (NOP receptor) agonist with Ki of 0.76 and 0.50 nM for rat and human ORL1 receptors, respectively. |
| PC-61541 |
W-212393
ORL1 agonist
|
W-212393 (MT-7716 free base) is a highly potent, brain penetrant ORL1 receptor (NOP receptor) agonist with Ki of 0.76 and 0.50 nM for rat and human ORL1 receptors, respectively. |
